Special Issue Introduction
Hepatitis B viral infection is one of the most important risk factors for hepatocellular carcinoma (HCC). The advent of potent antiviral therapy has revolutionized the management of chronic hepatitis B (CHB) and significantly reduced the development of HCC. However, significant number of HCC develops in patients on potent nucleos(t)de analogs (NAs) and patients with occult HBV infection.
In this issue, the current state-of-the-art perspectives will be provided on the risk of HBV-related HCC. The changing epidemiology of HCC is stressed with the development of sensitive diagnostic modalities and implementation of surveillance programs. The current evidence of modulation of HCC risk by NAs is summarized to shed light on the need for personalized approach in HCC surveillance. Serum biomarkers and liver stiffness measurement tools have been assessed for the feasibility of fine-tuning in HCC risk stratification in CHB. Statistical considerations have been given to tackle the issue of survival analysis with varying risks by effective risk-reducing treatment. Currently available risk prediction models have been reviewed for their robustness. Finally, the final goal will be the development of validation of comprehensive and personalized risk prediction system based on the individualized risk assessment for HBV-related HCC.
Epidemiology and risk factors of HCC in CHB
HCC risks in the era of nucleos(t) ide analog against HBV
Serum biomarkers for HCC risk prediction in CHB
Liver stiffness measurement for HCC risk prediction in CHB
Statistical issues for HCC risk prediction in CHB
HCC prediction models in CHB
HCC surveillance strategy based on individual risks in CHB
1. Grace Lai-Hung Wong Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.
2. Yao-Chun (Holden) Hsu Center of Liver Diseases, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
3. Cheng-Hao Tseng Division of Gastroenterology and Hepatology, Department of Internal Medicine, E-DA Cancer Hospital/I-shou University, Kaohsiung, Taiwan.
4. Feng Shen Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China.
5. Michael J. Bouchard Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, United States.
6. José Daniel Debes Department of Medicine, Gastroenterology and Hepatology, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
The list is arranged in no particular order and being updated.